Joseph Mikhael, MD

Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.

Dr. Mikhael outlines the significant hurdles in bispecific antibody therapy, as presented at the European Hematology Association's 2024 conference.

Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.

Dr. Mikhael discusses treatment in early relapse of multiple myeloma.

Bruce A. Feinberg, DO; Ryan Haumschild, PharmD, MS, MBA; Thomas Ollis, MS, RPh; and Joseph Mikhael, MD, discuss the future treatment landscape for the management of multiple myeloma.

Multiple myeloma experts comment on clinician education of novel therapies in the pipeline for multiple myeloma and discuss optimal routes of administration for currently available drugs.

Joseph Mikhael, MD, and Ryan Haumschild, PharmD, MS, MBA, discuss current and emerging trends in multiple myeloma treatment.

Thomas Ollis, MS, RPh, discusses the role of pharmacists and specialty pharmacy in the management of multiple myeloma.

A panel of experts in multiple myeloma review the use of quadruplet therapy in clinical practice and the impact on patients’ depth of response.

Joseph Mikhael, MD, reviews the phase 2 GRIFFIN trial evaluating the use of quadruplet therapy, daratumumab plus VRd, in patients with multiple myeloma, and the panel comments on the use of quadruplet therapy.

Multiple myeloma experts share insights on guiding treatment decisions to provide optimal care for patients.

Joe Mikhael, MD, provides an overview of minimal residual disease and assesses the prognostic impact for a patient with multiple myeloma.

Ryan Haumschild, PharmD, MS, MBA, comments on the use of triplet regimens as the standard of care treatment for patients with multiple myeloma, and Thomas Ollis, MS, RPh, shares a community practice perspective.

Joseph Mikhael, MD, reviews the history of multiple myeloma treatment and comments on the evolution of care.